Methods for detecting antibody that specifically bind a siderophore receptor polypeptide

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Epitopix, Llc patent solves the following problem:

The economic impact of infectious diseases in the production of food animals is well appreciated. Infectious diseases reduce profits, increase production costs, and endanger the overall reasonable food products, as well as the impact on performance, health and welfare of animals. This disease status can reduce the yield and quality of milk resulting in great economic losses to livestock herders. In some cases, microbial infection causes disease morbidity and mortality in newborn, young (eg, replacement stock) or adult animals.

Our analysis of this patent is as follows:

Epitopix, Llc’s patent US 8993252 B2 deals with Methods for detecting antibody that specifically bind a siderophore receptor polypeptide.
The present invention provides compositions including siderophore receptor polypeptides and Porins program from negative germs, and preferably, lipopolysaccharide in a concentration of no more than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Genes from 20q13 amplicon and their uses

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The The Regents Of The University Of California, , The Hospital For Sick Children patent solves the following problem:

This invention relates to the field of cytogenetics. Especially this invention relates to the identification of the gene in a region of the gains of the 20q13 in various types of cancer. The gene disclosed here can be used as probes specific for 20q13 Amplicon as well as for the treatment of various cancers.

Our analysis of this patent is as follows:

The Regents Of The University Of California, , The Hospital For Sick Children’s patent US 8993251 B2 deals with Genes from 20q13 amplicon and their uses.
The present invention relates to cDNA sequences from a region with gains of chromosome 20 associated with disease. The file can be used in Hybridization methods for identifying chromosomal abnormalities associated with various diseases. The file can also be used for the treatment of diseases.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Targeting human NAV1.7 variants for treatment of pain

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Kymab Limited patent solves the following problem:

It is recognized that every race people in their ranks and to just a few individuals in their genomes sequenced, for example, James Watson and Craig Venter. Comparing the genome of the man revealed a difference in their ranks in both coding and non-coding parts of the genome. With these differences in people are important and contribute to phenotypic differences between individuals. In extreme cases this can lead to genetic disease. The 1000 Genomes Project aims sorting sequences in the human genome, which includes a series of genomes in a very large sample of people from different art-recognized human ethnic population.

Our analysis of this patent is as follows:

Kymab Limited’s patent US 8992927 B1 deals with Targeting human NAV1.7 variants for treatment of pain.
The invention relates to human target interest (toi), anti-toi ligands, kits compositions and methods.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

PD-1 antibody

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Ucb Biopharma Sprl patent solves the following problem:

Our analysis of this patent is as follows:

Ucb Biopharma Sprl’s patent US 8993731 B2 deals with PD-1 antibody.
A humanized agonistic antibody that binds PD-1 in humans comprising a heavy chain wherein the variable domain of the heavy chain comprising the sequence given in SEQ ID NO: 1 for CDR- H1, the sequence given in SEQ ID NO: 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the heavy chain framework regions obtained from human sub-group in order VH4 3-1 4-30.4 + JH4 (SEQ ID NO: 33). exposure also extends to therapeutic uses of the antibody molecules, compositions and methods for the production of said antibody molecule.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Therapeutic approaches for treating CMT and related disorders

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Pharnext patent solves the following problem:

Our analysis of this patent is as follows:

Pharnext’s patent US 8992891 B2 deals with Therapeutic approaches for treating CMT and related disorders.
The present invention relates to compositions and methods for the treatment of Charcot-Marie-Tooth disease. Particularly, the invention relates to combined therapies for treating the disease by affecting PMP22 expression in a subject.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Biosensor for detecting multiple epitopes on a target

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Mediomics, Llc, , Saint Louis University patent solves the following problem:

Pathogenic bacteria are responsible for more than fifty infectious diseases. Methods allow the detection of pathogens in clinical, food, water and environmental samples is an important part of infectious disease diagnosis, treatment and prevention. In the meantime, pathogen detection include traditional methods based on cell culture and colony counting, antigen detection methods, PCR-based methods, and various biosensors. Each of these methods has its own strengths and weaknesses. Traditional methods are robust and sensitive, but very slowly. Antigen and PCR-based method is much faster, but technical and difficult in the case of PCR-based methods, prone to false positives. Biosensors offer the promise of much shorter detection periods but require further development before they become a real alternative. There is clearly a need for new detection methods to overcome the limitations of current existing technologies.

Our analysis of this patent is as follows:

Mediomics, Llc, , Saint Louis University’s patent US 8993245 B2 deals with Biosensor for detecting multiple epitopes on a target.
The present invention comprises a method of identifying a target consisting of a cycle epitope.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Labeled protein and method for obtaining the same

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Canon Kabushiki Kaisha patent solves the following problem:

The present invention relates to a labeled proteins for taking the labeled proteins with high purity and a way of getting the same. More particularly, the invention relates to a labeled antibody useful for diagnostic applications and a burnt its way.

Our analysis of this patent is as follows:

Canon Kabushiki Kaisha’s patent US 8993715 B2 deals with Labeled protein and method for obtaining the same.
It is a thing of the present invention to obtain a labeled protein, and especially, when the one labeled proteins and the same unlabeled proteins. There was a marked proteins including: a protein labeled with a protein target, at least one or more affinity interaction domain to bind to an affinity support, and at least one or more labeling places; and a labeling reagent bind at least one of the label areas; where the affinity of labeled proteins for brotherly support is the difference from the protein is labeled for the affinity support.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Monoclonal antibodies against NKG2A

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Innate Pharma S.A., , University Of Genova patent solves the following problem:

Maintaining effective immune surveillance without provoking autoimmune reactions requires the precise titration of effector T cell response. Many autoimmune disorders arise when the immune system mounts an immune response against self-antigens (see, for example, Ludewig et al (1999) Immunol Rev. 169 :. 45-54). While the mechanisms involved in the cause and maintain autoimmune reactions is unclear, it is likely that the image previously immunologically ignored antigens in secondary lymphoid organs involved

Our analysis of this patent is as follows:

Innate Pharma S.A., , University Of Genova’s patent US 8993319 B2 deals with Monoclonal antibodies against NKG2A.
The present invention relates to methods of treating immune diseases, especially autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic methods for treating such disorders. Generally, the present methods include the use of antibodies or other compounds that prevent the stimulation of NKG2A receptor on NK cells, leading to lysis of dendritic cells that contribute to the pathology of the disorder.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Circuit devices and methods having adjustable transistor body bias

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Suvolta, Inc. patent solves the following problem:

Integrated circuit (IC) devices (eg, chips) are mostly made of thousands, millions, or even billions of transistors on a single device. Proper operation of these devices usually requires precise time and performance among the various sections of the circuit. Sadly, the operation of these transistors may be subject to inevitable differences arising from many sources. Variations may arise from the manufacturing process used to fabricate the devices, between the device materials, changes in operating temperature, variations in power supply voltages, or even a device IC, the name but a few.

Our analysis of this patent is as follows:

Suvolta, Inc.’s patent US 8995204 B2 deals with Circuit devices and methods having adjustable transistor body bias.
Circuits, integrated circuit devices, and methods are disclosed that may include biasable transistors with screening position in the region under a gate, and separated from the gate in a semiconductor layer. Bias voltages can be applied to the screening region to optimize many aspects of performance, such as speed and current leakage. Particular embodiments may include narrow sections with between a high power supply voltage and a low power supply voltage, each with biasable transistors. One or more generation circuit can generate several voltages bias. A bias control section can couple a different bias voltages in screening regions biasable transistors to give a minimum speed and lower current leakage for such a minimum speed.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The The General Hospital Corporation patent solves the following problem:

Selective killing of particular types of cells is desirable in a variety of clinical conditions, including the treatment of cancer, which is often expressed through the growth and accumulation of malignant cells. An established treatment for cancer chemotherapy, which kills tumor cells by inhibiting DNA synthesis or damaging DNA (Chabner and Roberts, Nat. Rev. Cancer 5:65 (2005)). However, these treatments often cause severe systemic toxicity for nondiscriminatory killing normal cells. Because many cancer chemotherapeutics exert their efficacy by the selective destruction of growing cells, increased toxicities to normal tissues with high rates increase, as the bone marrow, gastrointestinal tract, and hair follicles are often prevented their use in optimal dose. Such treatments often fail, resulting in drug resistance, disease relapse and / or metastasis. To reduce systemic toxicity, in different ways examined to selectively target a particular cell population. Antibody and other ligands that recognize tumor-associated antigens with small molecule drugs or protein toxins, to produce conjugates and fusion proteins which are often referred to immunoconjugates and immunotoxins, respectively (Allen, Nat pin Cancer 2. 750 (2002)).

Our analysis of this patent is as follows:

The General Hospital Corporation’s patent US 8993295 B2 deals with Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting.
The present invention provides methods and compositions for the treatment of various diseases through selective killing of target cells using a combinatorial approach targets. invention showed protoxin fusion protein containing a cell targeting moiety and a modifiable activation moiety that activate an activation moiety not naturally operably found in, on, or around a target cell. These methods also include the combinatorial use of two or more therapeutic agents, at minimum comprising a protoxin and a protoxin activator, to target and destroy a specific cell population.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.